Connect with others exploring human genetics, hereditary traits, genome sequencing, and the latest advances in genetic medicine.
Posted by ExomeVsPanel · 41 replies
Whole-exome sequencing (WES) reads all approximately 20,000 protein-coding genes simultaneously, capturing both common and rare variants across the entire exome. A targeted gene panel, by contrast, examines only a predefined set of genes relevant to a specific condition or disease category, such as a hereditary cancer panel or a cardiomyopathy panel. WES is more comprehensive and useful when a patient's symptoms do not clearly point to one gene category, or when a rare disease diagnosis is being sought. Panel tests remain more cost-effective when a specific diagnosis is already strongly suspected, as they generate less complex data to interpret.
Posted by CRISPRBasics · 55 replies
CRISPR-Cas9 is a molecular tool derived from a bacterial immune defense system that allows scientists to precisely edit DNA sequences in living cells. The system uses a short RNA molecule called a guide RNA to direct the Cas9 protein enzyme to a specific DNA sequence, where it cuts both strands of the double helix. The cell's own repair mechanisms then either disable the cut gene or allow researchers to insert a new sequence. Clinical applications of CRISPR include treatments for sickle cell disease and beta-thalassemia, which received regulatory approval in late 2023. Research is ongoing for applications in cancer immunotherapy, viral infections, and inherited blindness.
Posted by HGPHistory · 38 replies
The Human Genome Project (HGP) was an international scientific collaboration that ran from 1990 to 2003, producing the first complete reference sequence of the 3.2-billion base pair human genome. It identified approximately 20,000-25,000 protein-coding genes and revealed that only about 1.5% of the genome codes for proteins, with the remainder comprising regulatory regions, repetitive elements, and sequences of undetermined function. The project generated foundational data that underpins all modern genomics research, drug development, and genetic medicine. A truly complete gapless human genome reference — the T2T-CHM13 assembly — was published in 2022 by the Telomere-to-Telomere consortium, filling the remaining gaps left by the HGP.
Posted by GeneticCounseling · 33 replies
Genetic counselors are health professionals trained in medical genetics and counseling who help individuals and families understand genetic test results, assess hereditary risk, and make informed decisions about genetic testing and medical management. You should consider genetic counseling if you have a personal or family history of inherited conditions, if genetic testing reveals variants of uncertain significance, before pursuing prenatal genetic testing, or when facing decisions about prophylactic surgeries based on genetic risk. In the United States, certified genetic counselors hold the CGC credential from the American Board of Genetic Counseling. Many major medical centers and cancer programs offer genetic counseling services.
Posted by ChromosomalAbnormality · 44 replies
Down syndrome (trisomy 21) results from the presence of an extra copy of chromosome 21, most commonly due to a process called nondisjunction during meiosis, where chromosome pairs fail to separate properly in the formation of eggs or sperm. The resulting egg or sperm carries two copies of chromosome 21 instead of one, and when fertilized by a normal gamete, the embryo has three copies of the chromosome. Maternal age is the strongest known risk factor for trisomy 21, with risk rising significantly after age 35. Chromosomal microarray analysis and prenatal sequencing can detect chromosomal abnormalities during pregnancy with high accuracy.
Posted by DeNovoMutations · 29 replies
De novo mutations are genetic changes that appear for the first time in an individual, not inherited from either parent. They arise from errors in DNA replication during the formation of eggs or sperm, or in the early cell divisions following fertilization. De novo mutations are responsible for a significant proportion of cases of severe neurodevelopmental conditions including autism spectrum disorder, intellectual disability, and epileptic encephalopathies. Parental age, particularly paternal age, influences the rate of de novo mutations because sperm are produced throughout a man's lifetime through continuous cell division, accumulating replication errors over time. Whole-genome sequencing of patient-parent trios (the patient plus both parents) is the most efficient way to identify de novo variants.
Posted by MitochrondrialDNA · 37 replies
Mitochondrial DNA (mtDNA) is a small circular genome of approximately 16,500 base pairs located in the mitochondria of every cell, separate from the nuclear genome. Unlike nuclear DNA, which is inherited from both parents, mtDNA is inherited exclusively from the mother and does not recombine, making it a stable marker for tracing maternal lineage. Ancestry tests analyze mtDNA haplogroups — groups of related mtDNA sequences that trace back to common maternal ancestors who lived in specific geographic regions thousands of years ago. mtDNA analysis has been instrumental in paleogenomics research, including the sequencing of Neanderthal and Denisovan genomes from ancient specimens.
Posted by DrugReactions · 46 replies
Many adverse drug reactions are caused by genetic variants that alter how the body metabolizes or responds to specific medications. The cytochrome P450 enzymes, encoded by genes like CYP2D6, CYP2C19, and CYP3A4, are responsible for metabolizing a large proportion of commonly prescribed drugs. Poor metabolizers — individuals with reduced-function variants — may accumulate drugs to toxic levels, while ultra-rapid metabolizers may clear them too quickly for therapeutic benefit. The FDA has added pharmacogenomic biomarker information to the labeling of over 250 drugs to guide prescribing based on known genotype-drug interactions. Pharmacogenomic testing before initiating certain medications can help prevent serious adverse events.
Posted by InheritancePatterns · 32 replies
In autosomal dominant inheritance, only one altered copy of a gene is sufficient to cause the associated condition; each child of an affected parent has a 50% chance of inheriting the variant. Examples include Huntington's disease, Marfan syndrome, and familial hypercholesterolemia. In autosomal recessive inheritance, two altered copies of a gene — one from each parent — are needed to cause the condition; carriers with one copy are typically unaffected. Cystic fibrosis, sickle cell anemia, and Tay-Sachs disease follow this pattern, with a 25% chance of an affected child when both parents are carriers. X-linked conditions involve genes on the X chromosome and affect males and females differently due to differences in X chromosome copy number.
Posted by NGSinCancer · 49 replies
Next-generation sequencing technologies allow simultaneous sequencing of hundreds to thousands of genes in tumor tissue, identifying somatic mutations that drive cancer growth. This approach, known as comprehensive genomic profiling, can detect actionable mutations that guide targeted therapy selection — for example, EGFR mutations in lung cancer that respond to tyrosine kinase inhibitors. NGS-based liquid biopsy, which analyzes circulating tumor DNA in blood, enables non-invasive tumor monitoring and early detection of treatment resistance. Major cancer centers now routinely use NGS profiling for solid tumors and hematologic malignancies to match patients with clinical trials and approved targeted therapies.
Join thousands of members sharing knowledge and experiences.